Illegal Chinese Biolab GUILTY — $4M Scam EXPOSED

A Chinese national operating an illegal biolab near California schools just got convicted on all counts for a $4 million COVID test scam that endangered American lives.

Story Snapshot

Federal jury in Sacramento convicts Jia Bei Zhu on 12 fraud counts after two-week trial on May 6, 2026.
Zhu sold over 1 million unauthorized COVID-19 test kits through Fresno-based Universal Meditech Inc., pocketing nearly $4 million.
Illegal Reedley biolab stored dangerous pathogens like HIV, hepatitis, TB, and malaria-labeled samples, discovered in 2022 near schools and water supply.
Links to Chinese funding exceed $1.3 million; Zhu used multiple aliases to deceive FDA and buyers.
Sentencing set for August 24, 2026, facing up to 20 years per fraud count, highlighting biosecurity failures.

Guilty Verdict Delivers Justice

A Sacramento federal jury convicted Jia Bei Zhu, a 64-year-old Chinese national, on all 12 counts on May 6, 2026. Prosecutors proved Zhu defrauded customers by selling over 1 million unapproved COVID-19 test kits for nearly $4 million from January 2020 to March 2023. He repackaged low-quality Chinese tests as FDA-approved through Universal Meditech Inc. and Prestige Biotech Inc. U.S. Attorney Eric Grant stated Zhu exploited the pandemic crisis and put lives at risk with misbranded devices.

Illegal Biolab Exposed National Security Risks

City code inspectors discovered Zhu’s covert biolab at 9330 S. Pleasant Ave. in Reedley in December 2022 during a business license check. The site stored risk group 2 and 3 pathogens including HIV, hepatitis, TB, and malaria, plus lab mice and traces of narcotics. Located near schools and the water supply, the unlicensed facility posed containment threats. CDC confirmed over 20 biohazards on-site in May 2023. Zhu hid ownership using aliases like Jiabei “Jesse” Zhu, David He, and Qiang He. FBI Sacramento Special Agent in Charge Sid Patel emphasized the dangers of misrepresented medical devices.

Zhu received over $1.3 million in wires from Chinese banks, fueling concerns over foreign influence in U.S. biosecurity. This mirrors a similar unauthorized biolab Zhu operated in Philadelphia, discovered in 2024 with degraded materials. House Select Committee on the Chinese Communist Party investigated CCP ties in November 2023, noting risks despite ruling out bioweapons intent.

Fraud Scheme Unraveled Through Investigation

Zhu lied to the FDA about his identity and role, distributing adulterated tests without emergency use authorization. An initial November 2023 indictment grew to 12 counts by superseding charges, including conspiracy to wire fraud, eight wire fraud counts, two for adulterated devices, and one false statement. Buyers relied on false FDA claims, receiving faulty tests during peak pandemic demand. Fresno County Chairman Garry Bredefeld praised the verdict as a clear message of accountability after local mitigation costs.

Investigations faced challenges from degraded samples at Reedley and Philadelphia sites, as FBI reported in March 2026. Despite this, prosecutors secured convictions across all charges. The case underscores gaps in federal tracking of biolabs and foreign-funded operations.

The Man Behind California’s Infamous Reedley Biolab Just Got Bad News From a Jury https://t.co/ap49LbhmRp

— Ω Paladin (@omega_paladin) May 7, 2026

Implications for Biosecurity and Oversight

Short-term, Zhu awaits sentencing before Judge Dale A. Drozd on August 24, 2026, potentially facing decades in prison and asset forfeiture. Reedley residents gain closure after years of uncertainty near hazardous materials. Long-term, the verdict sets precedent for prosecuting pandemic fraud and biosafety violations. It exposes oversight failures allowing unmonitored labs with dangerous pathogens. Communities bore cleanup costs, while buyers risked health from unreliable tests. This reinforces calls for stronger America First protections against foreign exploitation of U.S. vulnerabilities.

Both conservatives frustrated by lax borders and liberals wary of elite negligence share concerns over government failures enabling such threats. Enhanced FDA enforcement and policy reforms from the House Select Committee could prevent future incidents, safeguarding public health and national security.